Innocoll Inc

Michael Myers Appointed as Head of Portfolio Operations to Continue Guiding Late-Stage Clinical Programs.  

ATHLONE, Ireland, Dec. 8, 2014 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL) today announced that Tony Zook, formerly executive vice president, Global Commercial Operations, at AstraZeneca, has been appointed chief executive officer effectively immediately. Michael Myers, will continue with the company as head of Portfolio Operations. The executive changes were made to better position the company as its pipeline advances to late-stage clinical development and Innocoll prepares to become a fully-integrated specialty pharmaceutical company.

ATHLONE, Ireland, Nov. 13, 2014 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced financial and operating results for the three months and nine months ending September 30, 2014.

Innocoll to Report Third Quarter 2014 Financial Results and Host Webcast and Conference Call on November 13, 2014

ATHLONE, Ireland, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL) (the "Company"), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced that it will report third quarter 2014 financial results before the open of U.S. financial markets on November 13, 2014. Innocoll management will host a webcast and conference call at 10 a.m. EST that day to discuss the financial results and provide a corporate update.

Innocoll AG Proposes Changes to Supervisory Board and Stock Option Plan
ATHLONE, Ireland, Oct. 22, 2014 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today posted to shareholders a proposal to elect Joseph Wiley, M.D., a principal at Sofinnova Ventures, to its Supervisory Board. The Company also announced that Anthony H. Wild, Ph.D., has resigned from Innocoll's Supervisory Board. If Dr. Wiley's election is approved, Innocoll will have completed the new composition of its new Supervisory Board. In addition, the Supervisory Board is seeking shareholder support for a stock option plan that will enable it to strengthen and retain the team that will take Innocoll into the commercial stage of its development.

Innocoll AG Announces Closing of Initial Public Offering

ATHLONE, Ireland, Jul 25, 2014 (GLOBE NEWSWIRE via COMTEX) --
Innocoll AG (the "Company"), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced the pricing of its public offering of 6,500,000 American Depositary Shares ("ADSs"), each representing 1/13.25 ordinary shares, at a public offering price of $9.00 per ADS.